Higher Levels of SARS-CoV-2 Genetic Variation in Immunocompromised Patients : A Retrospective Case-Control Study
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection lasts longer in immunocompromised hosts than in immunocompetent patients. Prolonged infection is associated with a higher probability of selection for novel SARS-CoV-2 mutations, particularly in the spike protein, a critical target for vaccines and therapeutics.
METHODS: From December 2020 to September 2022, respiratory samples from 444 immunocompromised patients and 234 health care workers positive for SARS-CoV-2, diagnosed at 2 hospitals in Paris, France, were analyzed using whole-genome sequencing using Nanopore technology. Custom scripts were developed to assess the SARS-CoV-2 genetic diversity between the 2 groups and within the host.
RESULTS: Most infections were SARS-CoV-2 Delta or Omicron lineages. Viral genetic diversity was significantly higher in infections of immunocompromised patients than those of controls. Minor mutations were identified in viruses sequenced from immunocompromised individuals, which became signature mutations for newer SARS-CoV-2 variants as the epidemic progressed. Two patients were coinfected with Delta and Omicron variants. The follow-up of immunocompromised patients revealed that the SARS-CoV-2 genome evolution differed in the upper and lower respiratory tracts.
CONCLUSIONS: This study found that SARS-CoV-2 infection in immunocompromised patients is associated with higher genetic diversity, which could lead to the emergence of new SARS-CoV-2 variants with possible immune evasion or different virulence characteristics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:229 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 229(2024), 4 vom: 12. Apr., Seite 1041-1049 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guilbaud, Romane [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case-control |
|---|
| Anmerkungen: |
Date Completed 15.04.2024 Date Revised 15.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiad499 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364480556 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364480556 | ||
| 003 | DE-627 | ||
| 005 | 20240415233004.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiad499 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1376.xml |
| 035 | |a (DE-627)NLM364480556 | ||
| 035 | |a (NLM)37956413 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guilbaud, Romane |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Higher Levels of SARS-CoV-2 Genetic Variation in Immunocompromised Patients |b A Retrospective Case-Control Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2024 | ||
| 500 | |a Date Revised 15.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection lasts longer in immunocompromised hosts than in immunocompetent patients. Prolonged infection is associated with a higher probability of selection for novel SARS-CoV-2 mutations, particularly in the spike protein, a critical target for vaccines and therapeutics | ||
| 520 | |a METHODS: From December 2020 to September 2022, respiratory samples from 444 immunocompromised patients and 234 health care workers positive for SARS-CoV-2, diagnosed at 2 hospitals in Paris, France, were analyzed using whole-genome sequencing using Nanopore technology. Custom scripts were developed to assess the SARS-CoV-2 genetic diversity between the 2 groups and within the host | ||
| 520 | |a RESULTS: Most infections were SARS-CoV-2 Delta or Omicron lineages. Viral genetic diversity was significantly higher in infections of immunocompromised patients than those of controls. Minor mutations were identified in viruses sequenced from immunocompromised individuals, which became signature mutations for newer SARS-CoV-2 variants as the epidemic progressed. Two patients were coinfected with Delta and Omicron variants. The follow-up of immunocompromised patients revealed that the SARS-CoV-2 genome evolution differed in the upper and lower respiratory tracts | ||
| 520 | |a CONCLUSIONS: This study found that SARS-CoV-2 infection in immunocompromised patients is associated with higher genetic diversity, which could lead to the emergence of new SARS-CoV-2 variants with possible immune evasion or different virulence characteristics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a case-control | |
| 650 | 4 | |a genetic diversity | |
| 650 | 4 | |a genome dynamics | |
| 650 | 4 | |a immunocompromised patient | |
| 700 | 1 | |a Franco Yusti, Anna-Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Leducq, Valentin |e verfasserin |4 aut | |
| 700 | 1 | |a Zafilaza, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Bridier-Nahmias, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Todesco, Eve |e verfasserin |4 aut | |
| 700 | 1 | |a Soulie, Cathia |e verfasserin |4 aut | |
| 700 | 1 | |a Fauchois, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Le Hingrat, Quentin |e verfasserin |4 aut | |
| 700 | 1 | |a Kramer, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Goulenok, Tiphaine |e verfasserin |4 aut | |
| 700 | 1 | |a Salpin, Mathilde |e verfasserin |4 aut | |
| 700 | 1 | |a Daugas, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Dorent, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Ottaviani, Sébastien |e verfasserin |4 aut | |
| 700 | 1 | |a Zalcman, Gérard |e verfasserin |4 aut | |
| 700 | 1 | |a Ghosn, Jade |e verfasserin |4 aut | |
| 700 | 1 | |a Choquet, Sylvain |e verfasserin |4 aut | |
| 700 | 1 | |a Cacoub, Patrice |e verfasserin |4 aut | |
| 700 | 1 | |a Amoura, Zahir |e verfasserin |4 aut | |
| 700 | 1 | |a Barroux, Benoit |e verfasserin |4 aut | |
| 700 | 1 | |a Pourcher, Valérie |e verfasserin |4 aut | |
| 700 | 1 | |a Spano, Jean-Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Louet, Martine |e verfasserin |4 aut | |
| 700 | 1 | |a Marcelin, Anne-Geneviève |e verfasserin |4 aut | |
| 700 | 1 | |a Calvez, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Charpentier, Charlotte |e verfasserin |4 aut | |
| 700 | 1 | |a Descamps, Diane |e verfasserin |4 aut | |
| 700 | 1 | |a Marot, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Ferré, Valentine Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Coppée, Romain |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 229(2024), 4 vom: 12. Apr., Seite 1041-1049 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:229 |g year:2024 |g number:4 |g day:12 |g month:04 |g pages:1041-1049 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiad499 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 229 |j 2024 |e 4 |b 12 |c 04 |h 1041-1049 | ||